Covance CVD

  1. All
  2. Commentary
  3. Stock Reports
  4. Fund Reports
  5. Headlines
    1. Charles River Posts Solid 4Q as Preclinical Services Finally Rebound

      Commentary

      Thu, 13 Feb 2014

      growth since 2008. Management stated it is stealing market share from competitors, which we believe is accurate given that Covance reported just 5% revenue growth for its early-stage business in the fourth quarter.

    2. Covance 4Q Results Meet Expectations, Early-Stage Business Shows Signs of Improvement

      Commentary

      Wed, 5 Feb 2014

      Covance reported solid fourth-quarter results that ..... growth in the clinical development business. Covance ’s book-to-bill ratio held steady at ..... growth is sustainable over the near term. Covance was able to leverage the strong growth into

    3. Late-Stage Businesses Drive Narrow Moats for CROs

      Headlines

      Fri, 29 Nov 2013

      the CROs we cover: Quintiles Q, Covance CVD , Parexel PRXL, ICON ICLR, Charles ..... enrollment and drug development. Covance CVD estimates that more than 50 ..... development CROs we cover--Quintiles, Covance , ICON, and Parexel--fueled by

    4. Early-Stage Business Appears to be Bottoming as Covance Reports Strong Earnings Growth

      Commentary

      Wed, 30 Oct 2013

      Covance reported third-quarter results that met our ..... which bodes well for near-term growth. Covance ’s early-stage business appears to be ..... Charles River posted. On an adjusted basis, Covance ’s early-stage operating margin improved

    5. Charles River Posts Solid Earnings Growth Despite Ongoing Weakness in Early-Stage R&D Spending

      Commentary

      Wed, 30 Oct 2013

      growth this quarter, versus just 1% growth reported by Covance 's early-stage business. This outperformance has been ..... sales up 4.7% year to date, versus a 0.4% decline at Covance . Charles River's segment margin also increased slightly

    6. Pfizer Partnership Drives Margin Expansion in ICON's 3Q Results

      Commentary

      Thu, 24 Oct 2013

      operating margins, which would be in line with the margins currently posted by the late-stage businesses of competitors Covance and Quintiles. As a result of the strong quarter, management slightly raised its non-GAAP earnings per share guidance

    7. New Morningstar Analyst Report for Quintiles Transnational Holdings Inc

      Stock Reports

      Mon, 21 Oct 2013

      largely an unattractive business that lacks a competitive advantage.Quintiles' central lab business significantly trails Covance .Quintiles large size is likely to lead to slower growth than its peers.Quintiles leadership position allows it to benefit

    8. New Morningstar Analyst Report for Covance , Inc.

      Stock Reports

      Mon, 21 Oct 2013

      industrywide pricing for years to come. Covance invested $175 million to open its ..... because of industrywide oversupply. Covance has purchased Big Pharmaceutical ..... strategic partnerships, increasing Covance 's fixed costs and decreasing its

    9. Cramer's Lightning Round - One Of The Fastest Growing Companies In The Universe (8/12/13)

      Headlines

      Tue, 13 Aug 2013

      I like diagnostics. I'm not going to stop recommending that group, because the government likes diagnostics." Covance ( CVD ): "Best in show. It is one of these ancillary drug and healthcare plays that keep going higher." Complete Story

    10. Strong Central Lab Business Helps Drive Covance's Second-Quarter Earnings Growth

      Commentary

      Wed, 31 Jul 2013

      Covance CVD posted slightly better-than-expected ..... of 20%, despite the headwind caused by Covance 's increased technology investments in ..... improvement from 1.23 in the first quarter. Covance 's industry-leading central lab business

    « Prev12345Next »
    Content Partners